Interferon beta-1b Alternatives Compared
| Interferon beta-1b | Vumerity (diroximel fumarate) | Ocrelizumab |
|
|---|
| Interferon beta-1b | Vumerity (diroximel fumarate) | Ocrelizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Multiple Sclerosis, Colorectal Cancer, Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Interferon beta-1b may also be used for purposes not listed in this medication guide. |
Prescription only
Vumerity (generic name: diroximel fumarate) is an oral prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is given as a twice-daily medicine... View more |
Prescription only
Prescribed for Multiple Sclerosis. Ocrelizumab may also be used for purposes not listed in this medication guide. |
||||||||
| More about Interferon beta-1b | More about Vumerity (diroximel fumarate) | More about Ocrelizumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Interferon beta-1b has an average rating of 7.1 out of 10 from a total of 9 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 11% reported a negative effect. |
Vumerity has an average rating of 9.4 out of 10 from a total of 6 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Ocrelizumab has an average rating of 5.2 out of 10 from a total of 189 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Vumerity prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Betaseron, Extavia |
N/A |
Ocrevus | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
4.3 hours |
1 hour |
624 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 337 drugs are known to interact with Interferon beta-1b:
|
A total of 626 drugs are known to interact with Vumerity:
|
A total of 423 drugs are known to interact with Ocrelizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
October 29, 2019 |
March 28, 2017 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.